|
|
|
|
|
|
|
|
|
24.02.26 - 22:09
|
Inogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook (Business Wire)
|
|
|
Delivered full year revenue growth of approximately 4%
Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million
Well-positioned to accelerate expected 2026 revenue growth and profitabilityBEVERLY, Mass.--(BUSINESS WIRE)--$INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year.
“In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundamentals of our business. Our disciplined operational efficiency contributed to a substantial year-over-year improvement in adjusted EBITDA, culminating in a positive result for the first time since 2021,” said Kevin Smith, President and Chief Executive Officer. “Our s...
|
|
|
24.02.26 - 22:03
|
Inogen Announces $30 Million Share Repurchase Program (Business Wire)
|
|
|
BEVERLY, Mass.--(BUSINESS WIRE)--$INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has authorized a share repurchase program for up to $30 million of its outstanding common stock.
“This authorization reflects our confidence in Inogen's strategy, progress towards profitability goals, and long-term growth trajectory,” said Kevin Smith, President and Chief Executive Officer. “With a strong, debt-free balance sheet, we view this program as providing additional flexibility to deploy capital to support continued investment in innovation and portfolio expansion while enhancing shareholder value.”
The repurchase program will be financed through cash flow and existing cash reserves and is not expected to affect Inogen's capacity to pursue further growth initiatives. Authorization for the program will expire upon either December 31, 2027, or once the maximum...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.01.26 - 14:36
|
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025 (Business Wire)
|
|
|
Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 GOLETA, Calif.--(BUSINESS WIRE)--$INGN #AirwayClearance--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025.
The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%.
For the full year 2025, the Company expects to achieve positive Adjusted EBITDA, reflecting its continued commitment to financial discipline and effective cost management.
“While fourth quarter results continued to reflect strong performance in our business-to-business channels, we experienced a shi...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
